PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor ...

Gilead is laying off 149 workers in Foster City and Roche is laying off 108 workers in Santa Clara, adding to the mounting ...

UNAIDS Executive Director Winnie Byanyima said the sudden loss of American money has been 'devastating' for efforts to stop ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.